Art. -Nr.: HY-N0632

Esculentoside A

2 Cited Publications

Kundenbewertung

Based on 2 publication(s) in Google Scholar

Esculentoside A (EsA), a kind of triterpene saponin isolated from roots of Phytolacca esculenta. Esculentoside A (EsA) possesses anti-inflammatory activity in acute and chronic experimental models, has selective inhibitory activity towards cyclooxygenase-2 (COX-2). Esculentoside A (EsA) suppresses inflammatory responses in LPS-induced acute lung injury (ALI) through inhibition of the nuclear factor kappa B (NF-ΚB) and mitogen activated protein kinase (MAPK) signaling pathways.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.89%
CAS. Nr.: 65497-07-6
Formel: C₄₂H₆₆O₁₆
Molecular Weight:826.96

Speicherung:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

Esculentoside A Chemical Structure

CAS. Nr.: 65497-07-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Publications (2)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Esculentoside A (EsA), a kind of triterpene saponin isolated from roots of Phytolacca esculenta^[1]. Esculentoside A (EsA) possesses anti-inflammatory activity in acute and chronic experimental models^[2], has selective inhibitory activity towards cyclooxygenase-2 (COX-2)^[1]. Esculentoside A (EsA) suppresses inflammatory responses in LPS-induced acute lung injury (ALI) through inhibition of the nuclear factor kappa B (NF-ΚB) and mitogen activated protein kinase (MAPK) signaling pathways^[3].

Alle COX Isoform-spezifische Produkte anzeigen :

Alle NF-κB Isoform-spezifische Produkte anzeigen :

In Vitro

Esculentoside A (0-10 μM; 24 hours) reduced the release of TNF concentration in primed macrophages ^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Esculentoside A (EsA) (intraperitoneal injection; 20 mg/kg; once a day; 4 weeks) plays significant roles in the treatment of BXSB mice through modulation of inflammatory cytokines, inhibition of renal cell proliferation and induction of apoptosis ^[2].
? Esculentoside A (EsA) (injected intraperitoneally; 5, 10 and 20 mg/kg; once a day; 7 days) dose-dependently decreases the TNF, IL-1 and IL-6 levels in the sera of mice following LPS challenge^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BXSB mice^[2]
Dosage:

20 mg/kg
Administration:

Intraperitoneal injection; 20 mg/kg; once a day; 4 weeks
Result:

Alleviated the renal damage of LN.

Chemical Information

CAS. Nr. 65497-07-6
Appearance Solid
Molecular Weight 826.96
Formel C₄₂H₆₆O₁₆
Color White to off-white
SMILES

C[C@@]1(CC[C@]2(C(O)=O)[C@@]3([H])C[C@](C(OC)=O)(C)CC2)C3=CC[C@@]4([H])[C@]1(CC[C@]5([H])[C@@]4(C[C@H](O)[C@H](O[C@@](OC[C@@H](O[C@]([C@@H]([C@@H](O)[C@@H]6O)O)([H])O[C@@H]6CO)[C@@H]7O)([H])[C@@H]7O)[C@@]5(C)CO)C)C
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (2)

All IFWB

Sort by:

Journal Impact Factor

Phytomedicine

Esculentoside A alleviates cognitive deficits and amyloid pathology through peroxisome proliferator-activated receptor γ-dependent mechanism in an Alzheimer's disease model. [Abstract]

2022 Apr:98:153956. PMID: 35151213
Toxicol Lett

Human kidney organoids model of Esculentoside A nephrotoxicity to investigate the role of epithelial-mesenchymal transition via STING signaling. [Abstract]

2023 Jan 15:373:172-183. PMID: 36460195

Esculentoside A purchased from MedChemExpress. Usage Cited in: Toxicol Lett. 2023 Jan 15:373:172-183. [Abstract]

Esculentoside A causes mitochondrial membrane channel damage (the fluorescence intensity of Esculentoside A is lower than that of normal cells in kidney organoids).

Esculentoside A purchased from MedChemExpress. Usage Cited in: Toxicol Lett. 2023 Jan 15:373:172-183. [Abstract]

Esculentoside A (60 μM; 48 h) leads to downregulation of PGC-1α in kidney organoids.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (120.92 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.2092 mL

6.0462 mL

12.0925 mL

5 mM

0.2418 mL

1.2092 mL

2.4185 mL

10 mM

0.1209 mL

0.6046 mL

1.2092 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (3.02 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (3.02 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (3.02 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Zhong WT, et al. Protective effect of esculentoside A on lipopolysaccharide-induced acute lung injury in mice. J Surg Res. 2013 Nov;185(1):364-72. [Content Brief]

[2]. Wu F, et al. Synthesis, in vitro inhibitory activity towards COX-2 and haemolytic activity of derivatives of esculentoside A. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6430-3. Epub 2007 Oct 5. [Content Brief]

[3]. Ma H, et al. The effect of esculentoside A on lupus nephritis-prone BXSB mice. Arch Med Sci. 2013 Apr 20;9(2):354-60. [Content Brief]

[4]. Zhong WT, et al. Protective effect of esculentoside A on lipopolysaccharide-induced acute lung injury in mice. J Surg Res. 2013 Nov;185(1):364-72.

[5]. Ju DW, et al. Esculentoside A inhibits tumor necrosis factor, interleukin-1, and interleukin-6 production induced by lipopolysaccharide in mice. Pharmacology. 1998 Apr;56(4):187-95 [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.2092 mL	6.0462 mL	12.0925 mL	30.2312 mL
	5 mM	0.2418 mL	1.2092 mL	2.4185 mL	6.0462 mL
	10 mM	0.1209 mL	0.6046 mL	1.2092 mL	3.0231 mL
	15 mM	0.0806 mL	0.4031 mL	0.8062 mL	2.0154 mL
	20 mM	0.0605 mL	0.3023 mL	0.6046 mL	1.5116 mL
	25 mM	0.0484 mL	0.2418 mL	0.4837 mL	1.2092 mL
	30 mM	0.0403 mL	0.2015 mL	0.4031 mL	1.0077 mL
	40 mM	0.0302 mL	0.1512 mL	0.3023 mL	0.7558 mL
	50 mM	0.0242 mL	0.1209 mL	0.2418 mL	0.6046 mL
	60 mM	0.0202 mL	0.1008 mL	0.2015 mL	0.5039 mL
	80 mM	0.0151 mL	0.0756 mL	0.1512 mL	0.3779 mL
	100 mM	0.0121 mL	0.0605 mL	0.1209 mL	0.3023 mL

Keywords

Esculentoside A

2 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Esculentoside A

Immunology/Inflammation Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Glycoside Compound Library

Oxygen Sensing Compound Library

Terpenoids Library

Pyroptosis Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Food-Sourced Compound Library

Anti-Liver Cancer Compound Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Highly Selective Inhibitors Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Esculentoside A

Alle COX Isoform-spezifische Produkte anzeigen

Alle NF-κB Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (2)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Esculentoside A Related Classifications

HY-N0632 Related Classifications